A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~27 mi. (Beuvry, France, +144 more cities)

Clinique Ambroise Pare Beuvry ( Site 1213)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)

~27 mi. (Beuvry, France, +76 more cities)

Clinique Ambroise Paré ( Site 1007)

Non-Small Cell Lung Carcinoma

docetaxel, +1 more drug

chemotherapy, +1 more type

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~46 mi. (Lille, France, +93 more cities)

Polyclinique du Bois ( Site 0458)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~46 mi. (Lille, France, +199 more cities)

Hopital Claude Huriez CHRU LILLE ( Site 0440)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~46 mi. (Lille, France, +207 more cities)

Centre Oscar Lambret ( Site 0911)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~46 mi. (Lille, France, +137 more cities)

CHRU de Lille - Hopital Claude Huriez ( Site 0355)

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

~46 mi. (Lille, France, +201 more cities)

CHRU Lille - Hopital Claude Huriez /ID# 220991

Myelodysplastic Syndromes

azacitidine, +1 more drug

chemotherapy

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

~46 mi. (Lille, France, +127 more cities)

CHRU Lille - Hopital Claude Huriez /ID# 217916

Acute Myeloid Leukemia

azacitidine, +2 more drugs

chemotherapy

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

~46 mi. (Lille, France, +160 more cities)

Centre Oscar Lambret

FOLR1 Expression

Fallopian Tube Carcinoma, +2 more conditions

mirvetuximab soravtansine

chemotherapy, +1 more type

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

~46 mi. (Lille, France, +197 more cities)

CHRU Lille - Hopital Claude Huriez /ID# 217474

BCR-ABL1 Fusion, +47 more biomarkers

Acute Myeloid Leukemia

azacitidine, +1 more drug

chemotherapy

A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

~46 mi. (Lille, France, +156 more cities)

CHRU Lille - Hopital Claude Huriez /ID# 202213

IGH-CCND1 Fusion, +1 more biomarker

Multiple Myeloma

dexamethasone, +1 more drug

chemotherapy, +1 more type

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

~46 mi. (Lille, France, +228 more cities)

CHU Lille - Hôpital Albert Calmette /ID# 205105

MET Expression

Non-Small Cell Lung Carcinoma

telisotuzumab vedotin

chemotherapy, +1 more type